Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ONCX news out! Oncolix Sponsors Additional Research with MD Anderson Cancer Center
HOUSTON, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Oncolix, Inc., (OTCQB:ONCX) announced today that the Company has sponsored additional research with MD Anderson Cancer Center. The research will evaluate ProlantaTM for the potential treatment of additional gynecological cancers, in particular uterine cancer. Previous research funded at the MD Anderson Cancer Center resulted in the discovery of the mechanism of action of ProlantaTM (autophagy) and preclinical evidence of efficacy in ovarian cancer.
“Because Prolanta has the potential to treat all gynecological cancers, it is only fitting that we expand our focus to uterine cancer,” said Michael T. Redman, chief executive officer of Oncolix. “Like ovarian cancer, more than 80% of uterine cancer cells overexpress prolactin receptors, which are the molecular target for ProlantaTM. Similarly, the unmet medical needs for uterine cancer are similar to ovarian cancer.”
Prolanta™ is being evaluated in an open-label dose escalation Phase 1 clinical trial in patients with advanced ovarian cancer. Patients are divided into three dosing groups, or cohorts. Each sequential cohort will evaluate a higher dose of Prolanta™. Patients will be evaluated over a 99-day period. Initial dosing for 28 days is followed by a two-week safety assessment period, and then continues for an additional 56 days if no toxicities are observed. The first cohort, treated with the lowest dose, was completed, and has shown no serious adverse events or dose-limiting toxicity. Earlier this January, the Company announced it is now recruiting the mid-dose patients for this trial. For more information about the Phase 1 clinical trial please visit: https://clinicaltrials.gov/ct2/show/NCT02534922?term=Prolanta&rank=1
I keep quiet and buy a few almost every day ... these prices are a gift imo
$ONCX
$ONCX uplisted to OTC-QB as of today!
Oncolix, Inc., (OTC PINK:ONCX) announced today that the Company has been given approval by the OTC Markets to be listed and traded on the OTC-QB effective at the opening of trading on December 19, 2017.
“Our listing on the OTC-QB marks the end of the Company’s transition from Advanced Environmental Petroleum Producers (AEPP) to Oncolix, which has included our merger into AEPP, stock ticker and name change, new additions to the Company’s Board of Directors and an extensive review process by the Financial Industry Regulatory Authority (FINRA),” said Michael T. Redman, chief executive officer of Oncolix. “Completion of these objectives will now allow us to shift our focus toward advancing our clinical-stage asset, Prolanta™ in development for ovarian cancer. The next phase in the Company’s development will also be, to continue strengthening our public company infrastructure including the creation of a Scientific/Clinical Advisory board. This will be crucial in providing guidance for the continued development of Prolanta™ through the clinical trial process as well as advancing future therapeutic candidates.”
About Oncolix
Oncolix is a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian, uterine, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in its first indication, the treatment of ovarian cancer. This Phase 1 clinical trial is currently in progress. Prolanta™ is a prolactin receptor antagonist (or blocker) that has demonstrated efficacy in xenograft models through a unique mechanism of action, autophagy. In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ may be effective in breast, prostate and other cancers. In the current Phase 1 dose-escalation safety trial for the treatment of ovarian cancer, to date there have been no observed serious adverse events and no dose-limiting toxicities. The FDA has approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may result in reduced filing fees (currently $2 million), federal tax credits and marketing exclusivity.
source for the news: https://ih.advfn.com/p.php?pid=nmona&article=76320299
$ONCX uplisted to OTC-QB as of today!
Oncolix, Inc., (OTC PINK:ONCX) announced today that the Company has been given approval by the OTC Markets to be listed and traded on the OTC-QB effective at the opening of trading on December 19, 2017.
“Our listing on the OTC-QB marks the end of the Company’s transition from Advanced Environmental Petroleum Producers (AEPP) to Oncolix, which has included our merger into AEPP, stock ticker and name change, new additions to the Company’s Board of Directors and an extensive review process by the Financial Industry Regulatory Authority (FINRA),” said Michael T. Redman, chief executive officer of Oncolix. “Completion of these objectives will now allow us to shift our focus toward advancing our clinical-stage asset, Prolanta™ in development for ovarian cancer. The next phase in the Company’s development will also be, to continue strengthening our public company infrastructure including the creation of a Scientific/Clinical Advisory board. This will be crucial in providing guidance for the continued development of Prolanta™ through the clinical trial process as well as advancing future therapeutic candidates.”
About Oncolix
Oncolix is a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian, uterine, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in its first indication, the treatment of ovarian cancer. This Phase 1 clinical trial is currently in progress. Prolanta™ is a prolactin receptor antagonist (or blocker) that has demonstrated efficacy in xenograft models through a unique mechanism of action, autophagy. In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ may be effective in breast, prostate and other cancers. In the current Phase 1 dose-escalation safety trial for the treatment of ovarian cancer, to date there have been no observed serious adverse events and no dose-limiting toxicities. The FDA has approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may result in reduced filing fees (currently $2 million), federal tax credits and marketing exclusivity.
source for the news: https://ih.advfn.com/p.php?pid=nmona&article=76320299
here comes the ask slapping $ONCX
Oh I'm not worried one bit my friend ... I'm just taking advantage of the situation.
shaking the tree! keep em coming!
that makes two of us ;)
we need stronger bid support here
$ONCX
Happy thanksgiving to you as well my friend and to everyone else!
$AEPP
yes I did ...
Well it depends on how you look at it.
The person doing it thinks he is brilliant: put up a big wall to scare off buyers and force people to dump on his bids ...
It would be ridiculous if people fall for it.
This is someone holding a nice chunck but still hungry for more.
CDEL doing a last attempt to get some sellers with his 350k ask block
Not falling for it!
$AEPP
it's crazy GM26 ...
and off we go! $HPIL
I'd love that as well! if $IPLB is going crypto that would mean huge gains from current levels ... with a 320k float ... insanely thin
$AEPP moving!
great job microcaptrdr24, thanks for sharing! now let's spread the good word on $AEPP
time to buy is now imo
SPORTY, here's a recap of $AEPP's presentation yesterday at the microcap conference, I thought you might find it interesting ...
$IPLB where are those filings/news updates?
$AEPP ~ Oncolix, Inc. 2 filings today
Initial Statement of Beneficial Ownership (3) http://ih.advfn.com/p.php?pid=nmona&article=75803273
Amended Quarterly Report (10-q/a) http://ih.advfn.com/p.php?pid=nmona&article=75803448
microcap conference at 2:30 pm today as well
$AEPP ~ Oncolix, Inc. 2 filings today
Initial Statement of Beneficial Ownership (3) http://ih.advfn.com/p.php?pid=nmona&article=75803273
Amended Quarterly Report (10-q/a) http://ih.advfn.com/p.php?pid=nmona&article=75803448
microcap conference at 2:30 pm today as well
yes! sry 4 the misunderstanding then ... Let's rock this buddy!
$AEPP picking up steam, exposure is ramping up
multiple 8-k's and news out past few days
1. On September 28, 2017, Advanced Environmental Petroleum Producers Inc. (the “Company”) filed an amendment to its article of incorporation (the “Amendment”) with the Florida Secretary of State to change its name to Oncolix, Inc.
2. Oncolix, Inc. is a biotechnology company focused on gynecological cancers. Following the completion of the merger in August 2017, we have been focused on building an innovative biopharmaceutical company with the objective of developing and launching our lead candidate, Prolanta™, to treat ovarian and other cancers
4. Part of the process is to build the public company infrastructure that will first fulfill the OTC-QB requirement to have at least two independent directors and, ultimately, to qualify for a NASDAQ listing.
5. FLOAT 33,311,633
6. O/S 93,231,633
7. Oncolix, Inc. to Present at The MicroCap Conference on October 5th in New York City at the Essex House
$AEPP picking up steam, exposure is ramping up
multiple 8-k's and news out past few days
1. On September 28, 2017, Advanced Environmental Petroleum Producers Inc. (the “Company”) filed an amendment to its article of incorporation (the “Amendment”) with the Florida Secretary of State to change its name to Oncolix, Inc.
2. Oncolix, Inc. is a biotechnology company focused on gynecological cancers. Following the completion of the merger in August 2017, we have been focused on building an innovative biopharmaceutical company with the objective of developing and launching our lead candidate, Prolanta™, to treat ovarian and other cancers
4. Part of the process is to build the public company infrastructure that will first fulfill the OTC-QB requirement to have at least two independent directors and, ultimately, to qualify for a NASDAQ listing.
5. FLOAT 33,311,633
6. O/S 93,231,633
7. Oncolix, Inc. to Present at The MicroCap Conference on October 5th in New York City at the Essex House
$AEPP waking up, conference tmrw (one of the sponsors is MAXM)
conference tmrw $AEPP
picking up steam here ... soon we'll be attacking .10's and then .20's, .30's, .40's, .50's, ...
$AEPP monster is waking up imo
time to spread the good word on $AEPP
yes it does SPORTY, looks like AEPP is ramping up their IR ... exposure will start sending this up imo
uplisting to OTCQB and ultimately NASDAQ
https://ih.advfn.com/p.php?pid=nmona&article=75791177
$AEPP
$AEPP news out Oncolix Appoints Two Members to Its Board of Directors
Board Members bring Clinical and Manufacturing Expertise to Clinical-Stage Biopharmaceutical Company
Oncolix, Inc. (OTC PINK:AEPP) (the “Company”), a biotechnology company focused on gynecological cancers, announced on October 4, 2017, the Board of Directors voted to increase the number of directors to three from the current two and elected Jerry R. Youkey, M.D., and Dale Zajicek to serve on the Company’s Board of Directors. Mr. Zajicek is the first independent board member of the company.
Dr. Youkey and Mr. Zajicek have served as Directors of the Company’s wholly owned subsidiary, Oncolix, Inc., (a Delaware corporation) since 2007. In connection with such action, J. Donald Payne resigned as a director of the Company but continues to serve as its secretary. Michael T. Redman, chief executive officer of Oncolix, continues to serve as the Company’s third director. The term of all directors continues until their reelection or replacement by action of the stockholders of the Company.
“Following the completion of the merger in August 2017, we have been focused on building an innovative biopharmaceutical company with the objective of developing and launching our lead candidate, Prolanta™, to treat ovarian and other cancers,” said Michael T. Redman, president and CEO of Oncolix. “Part of that process is to build the public company infrastructure that will first fulfill the OTC-QB requirement to have at least two independent directors and, ultimately, to qualify for a NASDAQ listing. The appointment of Mr. Zajicek as an independent director assists with that objective. In addition, both appointees have already made valuable contributions and will be instrumental in adding additional world-class board members. Oncolix will soon be adding an independent fourth director, which will also fulfill the OTC-QB requirement.”
Jerry R. Youkey, M.D.
Jerry R. Youkey, M.D., joined Greenville Health System (GHS) in 1998, and currently serves as GHS Executive Vice President and Chief Academic Officer, reporting to the CEO. GHS is an eight-campus integrated delivery system with 1,756 beds, employing approximately 14,000 employees and 1,000 medical doctors. Since 2011, Dr. Youkey has additionally served as Founding Dean of University of South Carolina School of Medicine Greenville and in 2015, was appointed University of South Carolina Associate provost for Health Sciences Greenville.
Dr. Youkey served a rotating internship and general surgery residency at William Beaumont Army Medical Center, El Paso, TX, and a fellowship in peripheral vascular surgery at Walter Reed Army Medical Center, Washington D.C. He also served in the U.S. Army and was honorably discharged in August 1984, after attaining the rank of Colonel, Medical Corps. Dr. Youkey served as Chief, Department of Surgery and Director, Peripheral Vascular Surgery Fellowship Program at Geisinger Medical Center, Danville, PA, prior to coming to Greenville. He is certified by the American Board of Surgery in general vascular surgery.
He is widely published in his specialty field of general vascular surgery, having authored books, abstracts and journal articles. He holds the academic appointment of Professor and Associate Dean at the University of South Carolina, Columbia, SC. He received his B.A. from Stanford University, Palo Alto, CA, his medical degree from the Medical College of Wisconsin, Milwaukee, WI and is a member of numerous professional societies and organizations.
Dale Zajicek
Mr. Zajicek has over 37 years of experience in the pharmaceutical and biotechnology industry. In 2015, he retired as President of BioVectra, Inc., a company he joined in 1995. Following his promotion to Chief Operating Officer of BioVectra in 2005, he was responsible for growth of the firm’s contract manufacturing and drug development efforts, with the firm filing numerous Drug Master Files (DMF) and Investigational New Drug applications (IND) and supported the New Drug Applications for numerous clients. Mr. Zajicek successfully led BioVectra in the development of generic docetaxel, and obtained “first to file” status for this oncology drug. BioVectra partnered the product with Sandoz for the U.S. market, and other marketing firms for markets in Canada, Europe, Middle East, North Africa, and South America. Under Mr. Zajicek’s leadership, BioVectra has developed capabilities in microbial fermentation for protein-based and small molecule drugs, as well as combining biotech processing with synthetic capabilities to perform unique chemistries and conjugations of large to small molecules.
Prior to joining BioVectra, Mr. Zajicek held positions in manufacturing operations, engineering, research and product development, and business development at G.D. Searle and The NutraSweet Company. Mr. Zajicek holds a B.S. in Chemical Engineering from Illinois Institute of Technology and a B.S. in Business Administration from Elmhurst College.
Corporate contact:
Michael Redman
P: 281-402-3167
E: mredman@oncolixbio.com
Investor contact:
The Ruth Group
Robert Flamm
P: 646-536-7017
E: rflamm@theruthgroup.com
$AEPP ask side looks razor thin today!
thin both ways, hope to see some ask slapping soon.
$IPLB
$AEPP FL name change official now!
http://search.sunbiz.org/Inquiry/CorporationSearch/ByName
Type in Advanced Environmental Petroleum, click the first link.
WEEKLY BASIC CHART (source: stockscores.com)
http://charts.stockscores.com/chart.asp?TickerSymbol=AEPP&TimeRange=800&Interval=w&Volume=1&ChartType=CandleStick&ChartWidth=1024&ChartHeight=500&LogScale=None&Band=BB&avgType1=EMA&movAvg1=50&indicator1=MACD&Indicator2=AccDist&Indicator3=RSI&Indicator4=FStoch&candles=redgreen
$AEPP NinjaNotes ~ http://www.ddninja.com/AEPP
DAILY BASIC CHART (source: stockscores.com)
http://charts.stockscores.com/chart.asp?TickerSymbol=AEPP&TimeRange=400&Interval=d&Volume=1&ChartType=CandleStick&ChartWidth=1024&ChartHeight=500&LogScale=None&Band=BB&avgType1=EMA&movAvg1=50&indicator1=MACD&Indicator2=AccDist&Indicator3=RSI&Indicator4=FStoch&candles=redgreen
$AEPP NinjaNotes ~ http://www.ddninja.com/AEPP